Duspatalin - pharmacological agents from the group Myotropic antispasmodics. The active ingredient - mebeverin.
Structure and Composition Duspatalin
According to the instructions Duspatalin issued in the form of capsules prolonged action. 1 capsule containing 200 mg of active ingredient and auxiliary ingredients (magnesium stearate, talc, hypromellose, methacrylic acid, glycerol triacetate). The gelatin shell formulation includes gelatin and titanium dioxide. The contents of capsules looks like a small white granules.
Duspatalin packed in cardboard boxes, in each of which 2 or 3 blisters with capsules (10 units per blister).
The drug has antispasmodic effect. According to the instructions Duspatalin is selective spasmolytic effect on the smooth muscles of the gastrointestinal tract (especially in the colon). The drug has no effect on normal intestinal peristalsis, but also has an anticholinergic effect.
Duspatalin after ingestion is hydrolyzed (by reaction with water is converted into other chemical compounds). The drug is metabolized by the liver. Write mainly kidneys and a small amount of bile.
Capsules of this drug are capable of sustained release. According to the instructions Duspatalin - even after multiple dosing, accumulation is not observed its effect in the body.
Duspatalin shown with abdominal pain of spastic character (including the organic diseases), in hepatic and renal colic, intestinal dyskinesia and biliary tract. Also Duspatalin indications are: chronic pancreatitis (in the complex therapy), irritable bowel syndrome, chronic spastic colitis, menstrual pain in women.
Children older than 12 years Duspatalin shown in functional disorders of the gastrointestinal tract that are accompanied by abdominal pain.
Hypersensitivity to ingredients Duspatalin, children up to 12 years (due to the lack of clinical studies in this patient group).
Application Duspatalin during pregnancy and lactation
In clinical animal experiments teratogenic (damaging effect on the development of the fetus), the effect of the drug was not detected. Duspatalin can be used during pregnancy if the potential benefits of its higher risk to the fetus. The drug when taken in therapeutic doses, does not penetrate into breast milk, therefore its use during lactation is possible. In the opinion of Duspatalin used in the treatment of diseases of the digestive system in pregnant women with a positive effect, effects on the fetus were observed.
According to reviews Duspatalin can cause dizziness, rarely allergic reactions (urticaria, angioedema, rash).
Dosing and Administration Duspatalin
Take the drug should be inside, not liquid capsule and squeezed it with enough water. Duspatalin assigned before meals (for 20 minutes), 200 mg (1 capsule) twice a day.
In case of overdose with this drug indicated central nervous system excitation. Specific antidote in overdose Duspatalin not. Symptomatic treatment - gastric lavage, and other chelators.
Special instructions for use Duspatalin
Duspatalin not affect the ability to drive vehicles and the attention when handling potentially dangerous machinery.